SKYE

Skye Bioscience, Inc. (SKYE) Risks & Opportunities Analysis (2026)

Invetso Score: 6.1/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Risks

Score: 5.8 (Moderate)

Negative interest coverage and sub-1.0 current liquidity indicate financing sensitivity, leaving SKYE more exposed than better-capitalized peers if external funding conditions tighten.

Near-term balance-sheet flexibility appears limited versus peers with stronger liquidity buffers, which can constrain execution if demand softens or capital markets become less supportive.

The absence of meaningful operating cash-flow visibility versus profitable peers increases reliance on external financing, raising dilution or refinancing risk if market access weakens.

Extremely weak reported efficiency metrics suggest working-capital volatility, which can amplify earnings and cash-flow swings relative to peers with steadier conversion profiles.

Opportunities

Score:

Low net debt relative to EBITDA provides some balance-sheet headroom versus more levered peers, which can support resilience if operating conditions improve.

If external financing remains available, SKYE’s modest leverage could preserve optionality better than highly indebted peers, limiting downside from incremental capital needs.

Working-capital release could improve cash generation more sharply than peers with already efficient conversion, creating upside if operating normalization occurs.

A cleaner leverage profile than many small-cap peers may help SKYE participate in sector recovery without the same refinancing drag faced by more indebted competitors.

Overall Score

Score:

SKYE’s positioning is constrained by weak liquidity and cash-flow visibility versus peers, but relatively low net leverage and some balance-sheet optionality provide partial offset.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Skye Bioscience, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →